6-K 1 dp150675_6k.htm FORM 6-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of May 2021.

 

 

 

Commission File Number: 001-39071

 

ADC Therapeutics SA

(Exact name of registrant as specified in its charter)

 

Biopôle 

Route de la Corniche 3B 

1066 Epalinges 

Switzerland

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

 

Form 20-F

  Form 40-F

 

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  ADC Therapeutics SA
Date: May 5, 2021  
   
  By: /s/ Michael Forer
  Name: Michael Forer
  Title: Executive Vice President & General Counsel

 

 

EXHIBIT INDEX

 

Exhibit No. Description
99.1 Press release dated May 5, 2021